Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $82.84 in the prior trading day, Merck & Co Inc (NYSE: MRK) closed at $79.04, down -4.59%. In other words, the price has decreased by -$4.59 from its previous closing price. On the day, 16.23 million shares were traded.
Ratios:
Our goal is to gain a better understanding of MRK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.65. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.41. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.69.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 22, 2025, initiated with a Neutral rating and assigned the stock a target price of $85.
On February 18, 2025, Deutsche Bank Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $128 to $105.
TD Cowen Downgraded its Buy to Hold on February 10, 2025, whereas the target price for the stock was revised from $121 to $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 25 ’25 when Smart Dalton E. III sold 4,262 shares for $82.76 per share. The transaction valued at 352,723 led to the insider holds 7,778 shares of the business.
DALTON SMART bought 4,262 shares of MRK for $352,723 on Apr 25 ’25. On Feb 19 ’25, another insider, Oosthuizen Johannes Jacobus, who serves as the President, U.S. Market of the company, sold 8,500 shares for $84.09 each. As a result, the insider received 714,745 and left with 30,705 shares of the company.
Valuation Measures:
As of this moment, Merck’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.51, and their Forward P/E ratio for the next fiscal year is 8.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.11 while its Price-to-Book (P/B) ratio in mrq is 4.11.
Stock Price History:
Over the past 52 weeks, MRK has reached a high of $134.63, while it has fallen to a 52-week low of $75.93. The 50-Day Moving Average of the stock is -8.98%, while the 200-Day Moving Average is calculated to be -21.70%.
Shares Statistics:
A total of 2.52B shares are outstanding, with a floating share count of 2.51B. Insiders hold about 0.10% of the company’s shares, while institutions hold 80.40% stake in the company.
Earnings Estimates
As of right now, 15.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $2.45, with high estimates of $2.53 and low estimates of $2.33.
Analysts are recommending an EPS of between $9.05 and $8.79 for the fiscal current year, implying an average EPS of $8.92. EPS for the following year is $9.76, with 24.0 analysts recommending between $10.33 and $8.93.
Revenue Estimates
14 analysts predict $15.86B in revenue for the current quarter. It ranges from a high estimate of $16.23B to a low estimate of $15.52B. As of the current estimate, Merck & Co Inc’s year-ago sales were $16.11BFor the next quarter, 14 analysts are estimating revenue of $17.14B. There is a high estimate of $17.44B for the next quarter, whereas the lowest estimate is $16.81B.
A total of 24 analysts have provided revenue estimates for MRK’s current fiscal year. The highest revenue estimate was $66.43B, while the lowest revenue estimate was $64.16B, resulting in an average revenue estimate of $65.08B. In the same quarter a year ago, actual revenue was $64.17BBased on 24 analysts’ estimates, the company’s revenue will be $68.76B in the next fiscal year. The high estimate is $72.33B and the low estimate is $66.76B.
